[Trial of verification of the thymoanaleptic action of hypothalamic thyrostimulin (thyrotropin releasing factor of TRF) in melancholic states].
After the studies conducted by PRANGE and KASTIN in 1972, we tried to verify whether T.R.F. had a real thymo-analeptic effect and if a repeated administration could cure a depressive state. We used T.R.F. either intra-venously -- in slow perfusion or directly -- (1 mg per day) or p.o. (30 mg per day) on 18 mono or bipolar melancolic patients. The treatment lasted from 8 to 21 days. We have observed 4 good results obtained between the second and the sixth day, all among bipolar melancolic patients. In the other cases the results were negative. In all cases the tolerance was very good. These results, though very limited, present very interesting perspectives about a physiological substance whose site and actions are known with a relative precision.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use*
D013973:Thyrotropin-Releasing Hormone
Essai de vérification de l'action thymoanaleptique de la thyrostimuline hypothalamique (thyrotropine releasing factor ou TRF) dans les états mélancoliques